← Leaderboards
Daniel G. Schindler
Gtc Biotherapeutics, Inc.
$2,061,375
Attributed
$2,061,375
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $776.6K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$2,061,375 · 2
By mechanism
R44$1,461,375 · 1
R43$600,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Gtc Biotherapeutics, Inc.
Same institution · by research overlap
- Yann Echelard$100,000
- Robert A. Godke$100,000
- Carol Ziomek$100,000
Others in their field
Top investigators on “Neoplasm /Cancer Immunotherapy”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Charles A Coltman · Southwest Oncology Group$65,041,418
- Norman Wolmark · Nsabp Foundation, Inc.$63,095,441
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Samuel A Wells · Duke University$32,148,803
- George Wilding · University Of Wisconsin Madison$22,104,400
Research focus
Neoplasm /Cancer ImmunotherapyNod MouseScid MouseImmunologic Substance Development /PreparationSite Directed MutagenesisAntithrombinsAntineoplastic AgentsAnimalsAutoimmunityAutoimmune ProcessBaseBinding (Molecular Function)Biological Response Modifier TherapyBiopsyAntigen BindingBlotting, SouthernBlood SpecimenAntitumor ResponseB-LymphocytesBreastCaliberCancer ImmunotherapyCancer PatientBlood Cells
Grant awards (4)
CD137 AS A TARGET FOR THE IMMUNOTHERAPY OF CANCER$684,788
R44 · FY2007 · CA · contact PI
CD137 AS A TARGET FOR THE IMMUNOTHERAPY OF CANCER$776,587
R44 · FY2006 · CA · contact PI
CD137 AS A TARGET FOR THE IMMUNOTHERAPY OF CANCER$300,000
R43 · FY2005 · CA
CD137 AS A TARGET FOR THE IMMUNOTHERAPY OF CANCER$300,000
R43 · FY2004 · CA